Topic Hub
8 clinically reviewed articles, written and peer-reviewed by the HealthRX Medical Team.
Explore
Showing 8 of 8 clinical reviews.
A critical examination of the UKPDS 34 trial's enrollment biases, statistical caveats, generalizability gaps, and what post-publication commentary revealed about metformin's landmark evidence base.
Read clinical reviewA deep-dive into the UKPDS 34 trial design, randomization scheme, endpoint definitions, statistical methods, and how each methodological choice shapes the interpretation of metformin's 32% risk reduction in overweight type 2 diabetes.
Read clinical reviewDeep-dive into the health-economic modeling behind UKPDS 34, examining metformin's cost per QALY, payer-coverage rationale, and real-world pricing for overweight patients with type 2 diabetes.
Read clinical reviewDeep dive into the UKPDS 34 post-trial monitoring program, the legacy effect of early metformin therapy, and long-term safety and efficacy data that emerged after the original 1998 publication.
Read clinical reviewComplete breakdown of UKPDS 34 metformin outcomes including effect sizes, confidence intervals, secondary endpoints, and the 10-year time-course pattern in overweight type 2 diabetes.
Read clinical reviewDeep-dive into UKPDS 34 pre-specified and post-hoc subgroup analyses for metformin in overweight type 2 diabetes, examining responses by age, sex, BMI, and baseline biomarkers.
Read clinical reviewA deep-dive into UKPDS 34, the 1998 landmark trial that proved metformin reduces diabetes complications and death in overweight patients with type 2 diabetes, establishing it as first-line therapy worldwide.
Read clinical reviewA deep-dive into how UKPDS 34 reshaped metformin prescribing, which guidelines shifted, and what the trial's design means for patients who look nothing like the original cohort.
Read clinical review